OS Therapies Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OSTX research report →
Price Chart
About the company
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
- CEO
- Paul A. Romness
- IPO
- 2024
- Employees
- 5
- HQ
- Grasonville, MD, US
Get TickerSpark's AI analysis on OSTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $71.95M
- P/E
- -1.45
- Fwd P/E
- 1.74
- PEG
- 0.02
- P/S
- 0.00
- P/B
- -6.40
- EV/EBITDA
- 3.44
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 683.03%
- ROIC
- -0.60%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-363,085-12960.6%
- Op Income
- $-28,705,701
- Net Income
- $-28,753,844-223.7%
- EPS
- $-0.98-88.5%
- OCF Growth
- -195423.2%
- FCF Growth
- -195423.2%
- 52W High
- $2.57
- 52W Low
- $1.15
- 50D MA
- $1.65
- 200D MA
- $1.59
- Beta
- -0.73
- RSI (14)
- 50
- Avg Volume
- 630.08K
No earnings-call transcripts are available for OSTX yet.
- Free Float
- 57.0%
- Shares Outstanding
- 45.54M
- Float Shares
- 25.97M
of shares held by institutions
29 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 777.65K | ▲ 308.18K |
| Vanguard Group Inc | 540.42K | ▲ 352.16K |
| Cm Management, LLC | 400.00K | 0 |
| Geode Capital Management, LLC | 301.79K | ▲ 21.75K |
| Howard Financial Services, Ltd. | 248.00K | ▲ 2.56K |
| Blackrock, Inc. | 242.48K | ▲ 177.71K |
| Vanguard Fiduciary Trust Co | 174.13K | ▲ 57.47K |
| State Street Corp | 120.10K | ▲ 28.90K |
| Marshall Wace, Llp | 100.64K | ▲ 100.64K |
| Hightower Advisors, LLC | 85.55K | ▲ 70.35K |
| Northern Trust Corp | 70.82K | ▲ 4.76K |
| Beacon Pointe Advisors, LLC | 62.51K | 0 |
Held by 19 ETFs
Biggest fund positions in OSTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | EAGLE CRAIG | other | 0 |
| Dec 5, 24 | Romness Paul A. | other | 500,000 |
| Jan 22, 26 | McKean-Dieser Avril Suzette | other | 50,000 |
| Jan 22, 26 | Search Theodore F. | other | 50,000 |
| Jan 22, 26 | Ciccio John | other | 50,000 |
| Jan 22, 26 | Acevedo Christopher P. | other | 100,000 |
| Jan 22, 26 | PETIT ROBERT | other | 100,000 |
| Jan 22, 26 | Romness Paul A. | other | 1,000,000 |
| Jan 22, 26 | Jarry Olivier Roger | other | 50,000 |
| Jan 22, 26 | Galzahr Karim | other | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OSTX coverage
Recent articles, reports, and earnings notes.
No research on OSTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OSTX report →OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
newsfilecorp.com · Aug 17
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
newsfilecorp.com · Aug 13
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
newsfilecorp.com · Jul 8
OS Therapies Third Quarter 2026 Corporate Outlook
newsfilecorp.com · Jul 6
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
newsfilecorp.com · Jul 2
OS Therapies Provides U.S. Regulatory Update
newsfilecorp.com · Jun 30
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma
newsfilecorp.com · Jun 26
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
newsfilecorp.com · Jun 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.